Jean-Francois Korobelnik

Participe à 2 sessions

Sessions auxquelles Jean-Francois Korobelnik participe

Vendredi 20 Juin, 2025

Fuseau horaire: (GMT-05:00) Eastern Time (US & Canada)

A 96-week PULSAR Phase 3 trial post-hoc analysis: Rapid and sustained fluid control with aflibercept 8mg every 12 weeks or longer, as defined by fluid-free status at Weeks 16, 48, and 96 stratified by baseline CRT and BCVA - 5434

12:11 - 12:16 | 5 minutes

Vancouver Convention Centre (Édifice Est) - Ballroom B

Jean-Francois Korobelnik (Conférencier.ère)

12:16 - 12:19 | 3 minutes

Vancouver Convention Centre (Édifice Est) - Ballroom B